According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
A number of other analysts have also commented on the company. Morgan Stanley lifted their price target on Catalent from $46.00 to $50.00 and gave the stock an overweight rating in a report on Tuesday, April 16th. UBS Group lifted their price target on Catalent to $64.00 and gave the stock a buy rating in a report on Tuesday, July 23rd. ValuEngine upgraded Catalent from a hold rating to a buy rating in a report on Monday, April 15th. Finally, Jefferies Financial Group upgraded Catalent from a hold rating to a buy rating and lifted their price target for the stock from $50.00 to $62.00 in a report on Friday, June 21st. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $55.14.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 EPS for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.07. The business had revenue of $617.50 million for the quarter, compared to analyst estimates of $644.88 million. Catalent had a return on equity of 16.78% and a net margin of 6.01%. Catalent’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period last year, the company posted $0.41 earnings per share. As a group, research analysts forecast that Catalent will post 1.71 earnings per share for the current year.
In other Catalent news, SVP Steven L. Fasman sold 4,053 shares of the business’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $54.04, for a total value of $219,024.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Barry Littlejohns sold 15,940 shares of the business’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $53.53, for a total value of $853,268.20. The disclosure for this sale can be found here. Insiders have purchased 56,500 shares of company stock worth $2,542,845 over the last quarter. 1.40% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Sageworth Trust Co bought a new stake in shares of Catalent in the first quarter valued at $32,000. Evolution Wealth Advisors LLC bought a new stake in shares of Catalent in the second quarter valued at $32,000. Advisory Services Network LLC raised its stake in shares of Catalent by 115.5% in the second quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock valued at $39,000 after buying an additional 395 shares during the period. Financial Gravity Wealth Inc. bought a new stake in shares of Catalent in the first quarter valued at $47,000. Finally, Bremer Bank National Association bought a new stake in shares of Catalent in the first quarter valued at $49,000. Hedge funds and other institutional investors own 96.85% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: Trading on Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.